Scinai Immunotherapeutics (SCNI) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

11 May 2015

Indexes:

Not included

Website:

http://www.scinai.com

Description:

Scinai Immunotherapeutics (SCNI) focuses on developing innovative immunotherapy treatments for cancer and other diseases. The company aims to enhance the body's immune response to fight illnesses more effectively, offering hope for better patient outcomes through advanced medical research and technology.

Key Details

Price

$3.55

Market Cap

$2.97 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$16.00(+60.00% YoY)

PE Ratio

-

Annual ROE

142.26%

Annual Debt To Equity

-4.50

Beta

1.46

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Nov 21, 2024

Recent annual earnings:

May 15, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

May 21, 2024

Analyst ratings

Recent major analysts updates

No data about analysts updates

Screeners with SCNI included

Small cap stocks
NASDAQ earnings calendar
Biggest stock gainers today
Stocks with high beta
Stocks below SMA 200

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$3.55
SCNI price is $3.55

Price YTD Change

-40.34%
SCNI price is down -40.34% since January 1st

Price All-time High

$5110.00
SCNI price is currently -99.93% below its historical high of $5110.00

Market Cap

$2.97 M
SCNI market capitalization is $2.97 million

Beta

1.46
SCNI beta is 1.46

200-day SMA

$4.04
SCNI 200-day simple moving average is currently -12.02% below its 200-day simple moving average

14-day RSI

54.30
SCNI 14-day relative strength index is 54.30

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Net Income 3-Year Change

-369.14%
SCNI annual net profit is down -369.14% over the past 3 years

Annual EPS 3-Year Change

-28.62%
SCNI annual earnings per share is down -28.62% over the past 3 years

Annual Operating Profit

-$9.71 M
SCNI annual operaing income is -$9.71 million

Annual Operating Profit 3-Year Change

-525.55%
SCNI annual operaing income is down -525.55% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

142.26%
SCNI annual return on equity is 142.26%

Annual ROA

-37.20%
SCNI annual return on assets is -37.20%

Annual EBIT

-$9.71 M
SCNI annual earnings before interest & taxes is -$9.71 million

Annual EBITDA

-$9.19 M
SCNI annual earnings before interest, taxes, depreciation & amortization is -$9.19 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PB Ratio Sector Rank

12.03%
SCNI price to book ratio is higher than 12.03% of companies in Healthcare sector

PS Ratio Sector Rank

77.69%
SCNI price to sales ratio is higher than 77.69% of companies in Healthcare sector

Enterprise Value

$20.72 M
SCNI enterprise value is $20.72 million

Enterprise Value 1-Year Change

+28.01%
SCNI enterprise value is up +28.01% year-on-year

EV/EBITDA

-2.96
SCNI EV/EBITDA is -2.96

EV/EBITDA Sector Rank

32.98%
SCNI EV/EBITDA is higher than 32.98% of companies in Healthcare sector

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Debt To Equity Sector Rank

2.16%
SCNI annual debt to equity ratio is higher than 2.16% of companies in Healthcare sector

Annual Current Ratio

3.06
SCNI annual current ratio is 3.06

Annual Current Ratio Sector Rank

46.85%
SCNI annual current ratio is higher than 46.85% of companies in Healthcare sector

Annual Total Assets

$17.47 M
SCNI annual total assets is $17.47 million

Annual Current Assets

$5.45 M
SCNI annual total current assets is $5.45 million

Annual Total Liabilities

$22.04 M
SCNI annual total liabilities is $22.04 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

+58.41%
SCNI annual cash flow from operations is up +58.41% over the past 3 years

Annual CFI 3-Year Change

+65.49%
SCNI annual cash flow from investing activities is up +65.49% over the past 3 years

Annual CFF 3-Year Change

-74.54%
SCNI annual cash flow from financing activities is down -74.54% over the past 3 years

Annual FCF

-$10.02 M
SCNI annual free cash flow is -$10.02 million

Annual FCF 3-Year Change

+59.05%
SCNI annual free cash flow is up +59.05% over the past 3 years

Institutional Ownership

Similar stocks

NCNA logo
NuCana (NCNA)
BBLG logo
Bone Biologics (BBLG)
INM logo
InMed Pharmaceuticals (INM)
QNRX logo
Quoin Pharmaceuticals (QNRX)
NDRA logo
ENDRA Life Sciences (NDRA)
MTNB logo
Matinas BioPharma Holdings (MTNB)
LIFW logo
MSP Recovery (LIFW)
BDRX logo
Biodexa Pharmaceuticals (BDRX)
NBY logo
NovaBay Pharmaceuticals (NBY)
Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board
Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board
Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board
SCNI
prnewswire.com27 November 2024

JERUSALEM , Nov. 27, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced today that Dr. Jonathan Sadeh has been appointed as a member of the Company's Scientific Advisory Board (SAB).

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million
Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million
Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million
SCNI
prnewswire.com22 November 2024

JERUSALEM , Nov. 22, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its financial results for the nine months ended September 30, 2024 and provided a business update.

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies
Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies
Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies
SCNI
prnewswire.com16 September 2024

JERUSALEM, Israel , Sept. 16, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000
Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000
Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000
SCNI
prnewswire.com21 August 2024

JERUSALEM , Aug. 21, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI; "Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it has closed the previously announced Loan Restructuring Agreement (the "Restructuring Agreement") with its lender, the European Investment Bank (the "EIB").

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder
Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder
Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder
SCNI
prnewswire.com20 August 2024

JERUSALEM , Aug. 20, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it has entered into a $2 million Investment Commitment Agreement (the "Agreement") with RK Stone Miami LLC, an affiliate of Mr.

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity
Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity
Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity
SCNI
prnewswire.com13 August 2024

JERUSALEM , Aug. 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it has signed a definitive Loan Restructuring Agreement (the "Restructuring Agreement") with its lender, the European Investment Bank (the "EIB").

Why Is Scinai Immunotherapeutics (SCNI) Stock Up 56% Today?
Why Is Scinai Immunotherapeutics (SCNI) Stock Up 56% Today?
Why Is Scinai Immunotherapeutics (SCNI) Stock Up 56% Today?
SCNI
investorplace.com15 July 2024

Scinai Immunotherapeutics (NASDAQ: SCNI ) stock is taking off on Monday after the development stage biopharmaceutical company announced results from an early study. Scinai Immunotherapeutics revealed results from an in-vivo preclinical study of anti IL-17A/F VHH antibody fragment NanoAb.

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity
Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity
Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity
SCNI
prnewswire.com08 July 2024

JERUSALEM , July 8, 2024 /PRNewswire/ --  Scinai Immunotherapeutics Ltd . (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it has received an updated non-binding Letter of Intent ("LoI") from the European Investment Bank (the "EIB").

Scinai Publishes Q1 2024 Financial Results and Provides Business Update
Scinai Publishes Q1 2024 Financial Results and Provides Business Update
Scinai Publishes Q1 2024 Financial Results and Provides Business Update
SCNI
prnewswire.com02 July 2024

JERUSALEM , July 2, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its financial results for the quarter ended March 31, 2024, and provided a business update.

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.
Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.
Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.
SCNI
prnewswire.com13 June 2024

JERUSALEM , June 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it has received a non-binding Letter of Intent ("LoI") from the European Investment Bank (the "EIB").

FAQ

  • What is the primary business of Scinai Immunotherapeutics?
  • What is the ticker symbol for Scinai Immunotherapeutics?
  • Does Scinai Immunotherapeutics pay dividends?
  • What sector is Scinai Immunotherapeutics in?
  • What industry is Scinai Immunotherapeutics in?
  • What country is Scinai Immunotherapeutics based in?
  • When did Scinai Immunotherapeutics go public?
  • Is Scinai Immunotherapeutics in the S&P 500?
  • Is Scinai Immunotherapeutics in the NASDAQ 100?
  • Is Scinai Immunotherapeutics in the Dow Jones?
  • When was Scinai Immunotherapeutics's last earnings report?
  • When does Scinai Immunotherapeutics report earnings?

What is the primary business of Scinai Immunotherapeutics?

Scinai Immunotherapeutics (SCNI) focuses on developing innovative immunotherapy treatments for cancer and other diseases. The company aims to enhance the body's immune response to fight illnesses more effectively, offering hope for better patient outcomes through advanced medical research and technology.

What is the ticker symbol for Scinai Immunotherapeutics?

The ticker symbol for Scinai Immunotherapeutics is NASDAQ:SCNI

Does Scinai Immunotherapeutics pay dividends?

No, Scinai Immunotherapeutics does not pay dividends

What sector is Scinai Immunotherapeutics in?

Scinai Immunotherapeutics is in the Healthcare sector

What industry is Scinai Immunotherapeutics in?

Scinai Immunotherapeutics is in the Biotechnology industry

What country is Scinai Immunotherapeutics based in?

Scinai Immunotherapeutics is headquartered in Israel

When did Scinai Immunotherapeutics go public?

Scinai Immunotherapeutics's initial public offering (IPO) was on 11 May 2015

Is Scinai Immunotherapeutics in the S&P 500?

No, Scinai Immunotherapeutics is not included in the S&P 500 index

Is Scinai Immunotherapeutics in the NASDAQ 100?

No, Scinai Immunotherapeutics is not included in the NASDAQ 100 index

Is Scinai Immunotherapeutics in the Dow Jones?

No, Scinai Immunotherapeutics is not included in the Dow Jones index

When was Scinai Immunotherapeutics's last earnings report?

Scinai Immunotherapeutics's most recent earnings report was on 21 November 2024

When does Scinai Immunotherapeutics report earnings?

The date for Scinai Immunotherapeutics's next earnings report has not been announced yet